Abstract:Background:Although cigarette smoking is a risk factor for multiple disorders, it has long been thought to protect against Parkinson's disease (PD). Quantitative susceptibility mapping (QSM) is a novel magnetic resonance imaging (MRI)-based technique for assessing iron accumulation in vivo that has been widely applied in PD studies. This study aimed to investigate how cigarette smoking affects clinical performance of PD using quantified iron deposition as a proxy for PD pathology.Methods:In this observational study, we enrolled 35 male PD patients and 47 male healthy controls (HCs) and divided them into four groups. We performed an enhanced T2 star-weighted angiography (ESWAN) MRI sequence to measure the iron content of the nuclei within the nigrostriatal pathway. With the age and total intracranial volume (TIV) controlled as covariates, we performed inter-group comparisons of QSM values and moderation analyses for PD patients using smoking status and the smoking index (SI), respectively, as moderator variables.Results:The 2-way multivariate analysis of covariance (MANCOVA) results showed higher QSM values in the left red nucleus (P=0.024) in PD patients compared with those in HCs, and in the bilateral globi pallidi [left/right (L/R): P=0.009/0.003], substantia nigra pars compacta (SNc; L/R: P=0.001/0.037), and right substantia nigra pars reticulata (SNr; P=0.002) in non-smokers compared with smokers, with no marked interaction effect between PD and smoking status observed when applying the Bonferroni adjustment for multiple comparisons. Using cigarette smoking status and the SI as separate moderator variables, the moderation was shown up by a significant interaction effect in a disordinal and double-edged form. In our results, smoking-moderated protection for PD movement deficits emerged when PD was progressed. Among the affected deep brain nuclei, the nuclei most moderated by the impact of cigarette smoking on the interaction between brain iron and PD symptoms were the thalamus [smoking status associated with the Unified Parkinson's Disease Rating Scale (UPDRS) total score, P=0.04 (L); rigidity, P=0.03 (L); SI associated with UPDRS-III, P (L/R) =0.049/0.0497; rigidity, P (L/R) =0.01/0.02; bradykinesia, P (L/R) =0.048/0.04], the right red nucleus (SI associated with rigidity, P=0.04; bradykinesia, P=0.02), and the left SNc [smoking status associated with the Hoehn and Yahr (H&Y) stage, P=0.01].Conclusions:This was the first study investigating the impacts of current cigarette smoking on PD using quantified iron deposition. Our study confirmed the protective role of cigarette smoking against PD, consistent with the findings of previous studies. Furthermore, neuroprotection was present only when the PD pathology had progressed to a certain extent. In the interaction between iron deposition and clinical PD symptoms, our findings suggest that the thalamus, red nucleus, and SNc are likely to be the most affected nuclei moderated by cigarette smoking.

Autophagy and UPS pathway contribute to nicotine-induced protection effect in Parkinson's disease

Nicotine-mediated therapy for Parkinson's disease in transgenic Caenorhabditis elegans model

Nicotine-mediated Therapy for Parkinson’s Disease in Transgenic Caenorhabditis Elegans Model

Nicotine Ameliorates α-synuclein Pre-formed Fibril-Induced Behavioral Deficits and Pathological Features in Mice

Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson's disease

The molecular mechanism of preventive effect of nicotine on Parkinson's disease and Alzheimer's disease

Reduced Nicotinamide Adenine Dinucleotide Phosphate Inhibits MPTP-Induced Neuroinflammation and Neurotoxicity

Neural Substrates for the Association Between Cigarette Smoking and Parkinson's Disease

Protective Effects of Β- Nicotinamide Adenine Dinucleotide Against Motor Deficits and Dopaminergic Neuronal Damage in a Mouse Model of Parkinson's Disease

Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels

The Protective Role of Cigarette Smoking Against Parkinson’s Disease Via Moderation of the Interaction Between Iron Deposition in the Nigrostriatal Pathway and Clinical Symptoms

Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and α-synuclein accumulation in C. elegans models of Parkinson’s disease

[Protective Effect of Nicotinamide in a Mouse Parkinson's Disease Model].

Study of Apoptosis Pattern of Dopaminergic Neurons and Neuroprotective Effect of Nicotine in MPTP Mouse Model

Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson's disease

The Protective Effects of Nicotine from MPTP-induced Parkinson's Disease in C57BL Mice

NADPH Ameliorates MPTP-induced Dopaminergic Neurodegeneration Through Inhibiting P38mapk Activation

Preventive treatments to slow substantia nigra damage and Parkinson's disease progression: A critical perspective review

A Novel NOX Inhibitor Treatment Attenuates Parkinson’s Disease-Related Pathology in Mouse Models

Α7 Nicotinic Acetylcholine Receptor-Mediated Neuroprotection Against Dopaminergic Neuron Loss in an MPTP Mouse Model Via Inhibition of Astrocyte Activation

Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease